Abstract:Introduction Although treatment of obstructive sleep apnoea (OSA) using continuous positive airway pressure (CPAP) reduces blood pressure (BP), adherence to CPAP is often suboptimal. A mandibular advancement device (MAD) is a guideline-endorsed alternative therapy for OSA. Still, there is limited evidence on the relative efficacy between MAD and CPAP on BP reduction. We evaluate whether treatment of moderate-to-severe OSA using MAD can improve BP and other health-related outcomes compared with CPAP. Methods and analysis This is a randomised, controlled, non-inferiority trial conducted. We will recruit 220 Asians with a history of hypertension and high cardiovascular risk for an overnight polysomnography screening. Those with moderate-to-severe OSA (apnoea–hypopnoea index ≥15 events/hour) will be randomised to treatment with either MAD or CPAP in a 1:1 ratio. Stratified by age (60 vs <60 years old), body mass index (25 vs <25 kg/m 2 ) and apnoea–hypopnoea index (30 vs <30 events/hour), an adaptive randomisation scheme with permuted blocks constructed in real-time is implemented to restrict imbalance. The overall study duration is 12 months. The primary endpoint is the 24-hour mean arterial BP difference between baseline and 6-month follow-up. The secondary endpoints include other measures of ambulatory BP monitoring, arrhythmia based on a 4-day electrocardiographic monitoring, biomarker and proteomic analysis, cardiovascular magnetic resonance-derived myocardial fibrosis and remodelling and quality-of-life questionnaires. Recruitment began in October 2019 and ended in December 2022. Comparison between MAD and CPAP will be performed using covariance (ANCOVA) analysis of the changes in 24-hour mean arterial BP while adjusting for the baseline 24-hour mean arterial BP. We will compare the 95% CIs around the treatment difference point estimate with the prespecified non-inferiority margin (1.5 mm Hg). If the upper limit of the 95% CI is <1.5 mm Hg and crosses 0, non-inferiority of the MAD relative to CPAP will be established. Ethics and dissemination The Domain Specific Review Board-C, National Healthcare Group under approved the study protocol (NHG DSRB Ref: 2019/00359, approved on 28 August 2019). Study findings will be disseminated to various local, national, and international audiences through abstract presentations and publication in peer-reviewed journals. Trial registration number NCT04119999.

Continuous positive airway pressure adherence and blood pressure lowering in patients with obstructive sleep apnoea syndrome and nocturnal hypertension

A randomized controlled trial on ambulatory blood pressure lowering effect of CPAP in patients with obstructive sleep apnea and nocturnal hypertension

Beneficial Response of Blood Pressure to Short-Term Continuous Positive Airway Pressure in Chinese Patients with Obstructive Sleep Apnea-Hypopnea Syndrome.

Continuous positive airway pressure for treating high blood pressure of patients with obstructive sleep apnea-hypopnea syndrome：a meta-analysis

Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients

Influence of Continuous Positive Airway Pressure Treatment on Cardiovascular Risk Factors in Patients with Obstructive Sleep Apnea-Hypopnea Syndrome

[Impact of Long-Term Continuous Positive Airway Pressure Treatment for Patients with Obstructive Sleep Apnea Syndrome].

Effect of continuous positive airway pressure therapy on blood pressure variability of obstructive sleep apnea hypopnea syndrome

Analysis of the improvement of quality of life in patients with obstructive sleep apnea hypopnea syndromes associated hypertension with continuous positive airway pressure

Meta-analysis: the efficacy of continuous positive airway pressure therapy on blood pressure in obstructive sleep apnea hypopnea syndrom patients

Predictors of Long-Term Adherence to Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnea and Cardiovascular Disease in the Save Study

0493 A New Perspective on Exploring the Predictive Factors of Blood Pressure Reduction During CPAP Treatment in OSA

Effects of Continuous Positive Airway Pressure on Blood Pressure in Patients with Resistant Hypertension and Obstructive Sleep Apnea: a Systematic Review and Meta-Analysis of Six Randomized Controlled Trials

[Effects of Continuous Positive Airway Pressure on Daytime Sleepiness in Patients with Severe Obstructive Sleep Apnea Syndrome].

Effects of short-term continuous positive airway pressure treatment on arterial stiffness in patients with obstructive sleep apnea hypopnea syndrome]

Mandibular advancement device versus CPAP in lowering 24-hour blood pressure in patients with obstructive sleep apnoea and hypertension: the CRESCENT trial protocol

Nurse-led Intensive Interventions Improve Adherence to Continuous Positive Airway Pressure Therapy and Quality of Life in Obstructive Sleep Apnea Patients

Elevated Nocturnal and Morning Blood Pressure in Patients with Obstructive Sleep Apnea Syndrome

The effect of nCPAP short-term treatment on blood pressure and hs-CRP in refractory hypertension patients complicated with OSAHS

Continuous Positive Airway Pressure Effectively Ameliorates Arrhythmias in Patients with Obstructive Sleep Apnea-Hypopnea Via Counteracting the Inflammation

[Effects of Oral Appliance Treatment Upon Blood Pressure in Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome].